Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1.635 USD | +5.48% | +6.17% | -17.01% |
04-29 | Iterum Therapeutics Resubmits New Drug Application to U.S. Food and Drug Administration for Oral Sulopenem | CI |
03-28 | Transcript : Iterum Therapeutics plc, Q4 2023 Earnings Call, Mar 28, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-17.01% | 25.66M | |
+21.25% | 47.9B | |
+46.56% | 41.42B | |
-2.33% | 40.7B | |
-6.20% | 28.92B | |
+10.63% | 25.55B | |
-21.40% | 19.27B | |
-2.01% | 12.15B | |
+31.05% | 12.14B | |
-0.80% | 11.99B |
- Stock Market
- Equities
- ITRM Stock
- News Iterum Therapeutics plc
- Iterum Therapeutics : Says FDA Not Seeking Advisory Committee Review for Sulopenem Drug Application -- Stock Jumps 28% After-Hours